Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach
Open Access
- 18 June 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 16 (1), 1-10
- https://doi.org/10.1186/s12879-016-1610-3
Abstract
Despite a large increase in Clostridium difficile infection (CDI) severity, morbidity and mortality in the US since the early 2000s, CDI burden estimates have had limited generalizability and comparability due to widely varying clinical settings, populations, or study designs. A decision-analytic model incorporating key input parameters important in CDI epidemiology was developed to estimate the annual number of initial and recurrent CDI cases, attributable and all-cause deaths, economic burden in the general population, and specific number of high-risk patients in different healthcare settings and the community in the US. Economic burden was calculated adopting a societal perspective using a bottom-up approach that identified healthcare resources consumed in the management of CDI. Annually, a total of 606,058 (439,237 initial and 166,821 recurrent) episodes of CDI were predicted in 2014: 34.3 % arose from community exposure. Over 44,500 CDI-attributable deaths in 2014 were estimated to occur. High-risk susceptible individuals representing 5 % of the total hospital population accounted for 23 % of hospitalized CDI patients. The economic cost of CDI was $5.4 billion ($4.7 billion (86.7 %) in healthcare settings; $725 million (13.3 %) in the community), mostly due to hospitalization. A modeling framework provides more comprehensive and detailed national-level estimates of CDI cases, recurrences, deaths and cost in different patient groups than currently available from separate individual studies. As new treatments for CDI are developed, this model can provide reliable estimates to better focus healthcare resources to those specific age-groups, risk-groups, and care settings in the US where they are most needed. (Trial Identifier ClinicaTrials.gov: NCT01241552)Keywords
Funding Information
- Merck
This publication has 38 references indexed in Scilit:
- Burden of Clostridium difficile on the Healthcare SystemClinical Infectious Diseases, 2012
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus VancomycinClinical Infectious Diseases, 2012
- Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial ManagementClinical Infectious Diseases, 2012
- The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based StudyAmerican Journal Of Gastroenterology, 2012
- Multicenter Study of Clostridium difficile Infection Rates from 2000 to 2006Infection Control & Hospital Epidemiology, 2010
- Postoperative Clostridium difficile-associated diarrheaSurgery, 2010
- The Changing Epidemiology of Clostridium difficile InfectionsClinical Microbiology Reviews, 2010
- Clostridium difficileInfections among Hospitalized Children, United States, 1997–2006Emerging Infectious Diseases, 2010
- Clostridium difficile–related Hospitalizations among US Adults, 2006Emerging Infectious Diseases, 2009
- Hospital-acquired Clostridium difficile-associateddisease in the intensive care unit setting: epidemiology, clinical course and outcomeBMC Infectious Diseases, 2007